Aetna modified CPB 1040 for elranatamab-bcmm (Elrexfio), effective December 11, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its Elrexfio coverage policy under CPB 1040 Aetna system, governing medical necessity criteria for elranatamab-bcmm in relapsed or refractory multiple myeloma. The primary billing code affected is HCPCS J1323 (injection, elranatamab-bcmm, 1 mg), with administration billed under CPT 96401. If your oncology or hematology practice treats heavily pre-treated myeloma patients on Aetna commercial plans, this policy sets the exact criteria that determine whether your claims pay or deny.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Elranatamab-bcmm (Elrexfio) — CPB 1040 |
| Policy Code | CPB 1040 |
| Change Type | Modified |
| Effective Date | December 11, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology, Medical Oncology, Infusion/Specialty Pharmacy |
| Key Action | Confirm four prior therapy lines—including anti-CD38, proteasome inhibitor, and IMiD—before submitting prior authorization for J1323 |
Aetna Elranatamab-bcmm Coverage Criteria and Medical Necessity Requirements 2025
The Aetna elranatamab-bcmm coverage policy has one core requirement: four prior lines of therapy, with specific drug classes in each line. No shortcuts, no exceptions.
To meet medical necessity for initial approval, your patient must have relapsed or refractory multiple myeloma (ICD-10 C90.00 or C90.02) and have received at least four prior therapies. Those therapies must include at least one drug from each of these three categories:
| # | Covered Indication |
|---|---|
| 1 | Anti-CD38 monoclonal antibody — daratumumab (J9144, J9145) or isatuximab (J9227) |
| 2 | Proteasome inhibitor — bortezomib (J9041, J9046, J9048, J9049) or carfilzomib (J9047) |
| 3 | Immunomodulatory agent (IMiD) — lenalidomide, pomalidomide, or thalidomide |
The real issue here is documentation. Aetna wants evidence that the patient received all three drug classes as part of their treatment history. Your prior authorization submission needs to show that clearly—drug names, dates, and lines of therapy—or expect a denial.
Elranatamab-bcmm billing requires precertification on all Aetna commercial plans. Call (866) 752-7021 or fax (888) 267-3277. You can also use Aetna's Specialty Pharmacy Precertification SMN forms. Do not submit J1323 without a precertification number in place. That's a clean path to a claim denial.
For reimbursement continuation, Aetna allows reauthorization when there's no evidence of unacceptable toxicity or disease progression. That's a relatively clean standard—it shifts the burden to you to document stable response at each reauthorization cycle.
Aetna Elranatamab-bcmm Exclusions and Non-Covered Indications
Aetna is direct here: all indications outside relapsed or refractory multiple myeloma with the four-prior-therapy requirement are experimental, investigational, or unproven.
That means if your provider is using Elrexfio for any other diagnosis—or even for myeloma patients who haven't completed the required prior therapy sequence—Aetna will not cover it under this coverage policy. There's no pathway for off-label use, expanded criteria, or early-line treatment at this time.
If your practice is trialing elranatamab-bcmm in a clinical context that doesn't match these criteria, talk to your compliance officer before submitting any claims. Billing J1323 outside the approved indication is a denial risk and potentially a billing integrity issue.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Relapsed or refractory multiple myeloma — ≥4 prior therapies including anti-CD38, proteasome inhibitor, and IMiD | Covered | J1323, C90.00, C90.02 | Prior authorization required; precertify via (866) 752-7021 |
| Continuation of therapy — no toxicity or progression | Covered (with reauth) | J1323, C90.00, C90.02 | Reauthorization required; document stable response |
| Multiple myeloma — fewer than 4 prior lines, or missing required drug class | Not Covered | C90.00, C90.02 | Considered experimental/investigational |
| All other indications | Not Covered | — | Considered experimental, investigational, or unproven |
Aetna Elranatamab-bcmm Billing Guidelines and Action Items 2025
The effective date is December 11, 2025. If you're billing J1323 on Aetna commercial plans now or planning to, these steps apply immediately.
| # | Action Item |
|---|---|
| 1 | Audit your active Elrexfio patients before submitting any new prior authorizations. Pull the therapy history for each patient. Confirm they've had at least four prior lines and that each required drug class is documented. If the record is incomplete, get the clinical team to fill the gaps before you submit. |
| 2 | Update your prior authorization workflow to capture all three required drug classes. Build a checklist into your PA intake process: anti-CD38 agent, proteasome inhibitor, IMiD. All three must be documented. Missing one is a denial. |
| 3 | Bill J1323 at the correct unit. HCPCS J1323 is billed per 1 mg of elranatamab-bcmm. Confirm your charge capture reflects the exact dose administered. Over- or under-reporting units on a specialty oncology drug is a high-exposure error. |
| 4 | Bill administration under CPT 96401 for subcutaneous or intramuscular chemotherapy administration. Elrexfio is administered subcutaneously. CPT 96401 is the correct administration code. Confirm your charge capture has this linked correctly to J1323 in your EHR or billing system. |
| 5 | Set a reauthorization calendar for every active patient. Aetna requires reauth at continuation. Document response status at each cycle. Your authorization team should track expiration dates and trigger renewal requests with updated clinical notes before the current auth lapses. |
| 6 | Confirm plan design before submitting. This policy applies to Aetna commercial medical plans. Medicare criteria are separate—see Aetna's Medicare Part B step therapy criteria. If you're unsure which plan applies for a given patient, verify before submitting precertification. Sending a commercial PA request for a Medicare Advantage patient (or vice versa) wastes time and delays treatment. |
| 7 | Loop in your compliance officer if you have any patients receiving Elrexfio off-label. The policy is explicit that all other indications are experimental. If there's any ambiguity about whether a patient's situation fits the criteria, get a compliance review before the claim goes out. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Elranatamab-bcmm Under CPB 1040
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J1323 | HCPCS | Injection, elranatamab-bcmm, 1 mg |
Supporting HCPCS Codes (Prior Therapy Documentation — Not Billed for Elrexfio)
These codes represent the prior therapies Aetna requires in the patient's history. You're not billing these for the Elrexfio encounter—they're what you need documented in the treatment history to support medical necessity.
| Code | Type | Description |
|---|---|---|
| J9041 | HCPCS | Injection, bortezomib, 0.1 mg |
| J9046 | HCPCS | Injection, bortezomib (Dr. Reddy's), not therapeutically equivalent to J9041, 0.1 mg |
| J9047 | HCPCS | Injection, carfilzomib, 1 mg |
| J9048 | HCPCS | Injection, bortezomib (Fresenius Kabi), not therapeutically equivalent to J9041, 0.1 mg |
| J9049 | HCPCS | Injection, bortezomib (Hospira), not therapeutically equivalent to J9041, 0.1 mg |
| J9144 | HCPCS | Injection, daratumumab, 10 mg and hyaluronidase-fihj |
| J9145 | HCPCS | Injection, daratumumab, 10 mg |
| J9227 | HCPCS | Injection, isatuximab-irfc, 10 mg |
Note: Lenalidomide, pomalidomide, and thalidomide do not have specific HCPCS injection codes listed in this policy. Document these agents by name, NDC, and dates in the clinical record and PA submission.
CPT Administration Codes
| Code | Type | Description |
|---|---|---|
| 96401 | CPT | Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic |
ICD-10-CM Diagnosis Codes
| Code |
|---|
| C90.00 |
| C90.02 |
Note: CPB 1040 references these codes without providing text descriptions. For standard ICD-10-CM descriptions, see the official CMS ICD-10-CM code set.
Pair one of these ICD-10 codes with J1323 on every claim.
Get the Full Picture for CPT 96401
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.